The administration of WT1-specific CD8+ cytotoxic T-cell (CTL) clones after Hematopoietic stem cell transplantation to relapsed or high-risk leukemia patients led to detectable long term maintenance and clinical responses without evidence of on-target toxicity [16]. This evidence concerns the gene WT1 and leukemia.